PDF file       product list       search       home page       email       legal notice    

ABX  advanced biochemical compounds   


Catalogue
Number
Product Order number / Unit

9702 DOTATOC (GMP) Please contact  
ITG Isotope Technologies Garching GmbH  
Sales Dept.   
Lichtenbergstr. 1  
D-85748 Garching, Germany  
Phone +49 89 289 13908  
Fax +49 89 289 13929 
Please inquire for customized filling and bulk quantities.

 
Precursor for radiolabelled DOTA-TOC
Ligand for somatostatin receptors
Manufactured according to GMP requirements for APIs for use in clinical trials (ICH Q7 chapter 19)
Molar Mass: 1421.7 (net peptide)
C65H92N14O18S2
[204318-14-9]
White to off-white solid packaged in plastic vials
Purity: ≥ 98 %
Certificates:
CoA with HPLC (identity, purity, assay); GC (residual Solvents, water content, counter-ion); microbiology test
Chemical Name:
Sequence: DOTA-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr(ol), cyclic disulfide
Synonymes:
DOTA-TOC acetate; DOTA-[Tyr3]-octreotide; Edotreotide; CA index name: L-Cysteinamide, N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic(2→7)-disulfide, supplied as acetate salt
Literature:
Forrer F. et al. Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors. Anticancer Res. 2006, 26, 703-707.
Koukouraki S. et al. Evaluation of the pharmacokinetics of (68)Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for (90)Y-DOTATOC therapy. Eur. J. Nucl. Med. Mol. Imaging 2006, 33, 460-466.
date of product catalogue issue: 24 February 2017

 
 
 

  PDF file       product list       home page       search       email       legal notice